Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Chronic hepatitis B infection remains a serious global health threat, contributing to large numbers of deaths through liver cirrhosis and hepatocellular carcinoma. Current treatment does not eradicate disease and therefore new treatments are urgently needed. In acute HBV a strong immune response is necessary to clear the virus, but in chronic infection the immune response is weakened and dysfunctional. Therapeutic vaccination describes the process of inoculating individuals with a non-infective form of viral antigen with the aim of inducing or boosting existing HBV specific immune responses, resulting in sustained control of HBV infection. In this review we outline the rationale for therapeutic vaccination in chronic HBV infection, discuss previous and ongoing trials of novel HBV therapeutic vaccine candidates and outline strategies to improve vaccine efficacy going forward.

Original publication

DOI

10.1111/cei.13614

Type

Journal article

Journal

Clin Exp Immunol

Publication Date

09/05/2021

Keywords

Hepatitis B, T cell, immunotherapy, vaccination